FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900341805> ?p ?o ?g. }

• W2900341805 abstract "Abstract Abstract 2805 CHOP – based chemotherapy for aggressive lymphomas in patients with age-adjusted International Prognostic Index (IPI) score of 2–3 resulted in a historical 3-year progression free survival of approximately 30% in a previous Nordic phase III study. The aim of the present study is to determine whether an intensified regimen with chemoimmunotherapy and CNS prophylaxis improves outcome. Methods: From October 2004 to June 2008 patients were included in a phase II study. Inclusion criteria: 1) Age 18–65 years. 2) Newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade III. 3) No clinical sign of CNS disease and negative CSF cytology/flow cytometry by lumbar puncture. 4) No HIV infection. 5) WHO performance score 0–3. 6) Adequate organ functions. Schedule: Six courses of R-CHOEP14. Pegfilgrastim 6 mg sc. day four of each cycle. One course of high dose cytarabine 12 g/m2 (6 g/m2 for patients 60–65 years). One course of high dose methtrexate 3 g/m2 (1 g/m2 for patients 60–65 years). Biopsy and/or 18FDG PET/CT imaging of residual masses after fulfilled therapy was recommended, but not mandatory. Radiotherapy was given to residual masses of uncertain significance. Results. Demographic data:.156 eligible patients were included (97 males). Median age: 54 years (range 20–64). Histology: DLBCL: 145, FL grade 3: 12 (three patients no data). Age adjusted IPI score: 2: 117; 3: 39. Stage III-IV: 150 patients. LDH elevated: 151 patients. Performance status 2–3: 51 patients. B-symptoms were registered in 97 patients, more than one extranodal site in 42 and bulky lesions (≥ 10 cm) in 68. Median observation time for patients alive at last follow up was 36 months. Toxicity: Three toxic deaths are registered, one large bowel perforation, one fulminant hepatic necrosis and one septic shock. Hematological toxicity grade 4 was seen in 78% of the patients, infection grade 4 in 8%. Radiotherapy was given to 16% of the patients. Response: Response rates at end of therapy: CR/CRu: 69%, PR: 22%, SD: 1%, PD: 4.5%. Seventeen patients (7%) were not treated according to protocol, either due to lack of response (6 patients) or due to toxicity (eleven patients). The majority of the PR patients were considered to have residual masses and not viable tumour tissue. Survival: Three year overall survival was 80% (95% CI +/− 6.5%) and three year treatment failure free time 67% (95% CI +/−8.0%). CNS events: Seven patients had a CNS relapse, all but one were isolated (4 intracerebral, 3 meningeal). All CNS relapses occurred within 6 months after inclusion. Conclusions: The results are promising with a low three year treatment failure rate, a low toxic death rate and fewer CNS events than expected. The CNS events might be further reduced by earlier CNS prophylaxis. The study was supported by an unrestricted grant from Amgen Disclosures: Holte: Roche: Honoraria, Research Funding; Amgen: Honoraria, Research Funding. LeppÃ: Roche: Honoraria. Bjorkholm:Roche: Research Funding. Jyrkkiö:Roche: Honoraria. Kolstad:Roche: Honoraria; Amgen: Honoraria. Fosså:Roche: Honoraria. φstenstad:Roche: Honoraria; Amgen: Honoraria. Eriksson:Amgen: Research Funding." @default.
• W2900341805 created "2018-11-16" @default.
• W2900341805 creator A5004214099 @default.
• W2900341805 creator A5010189385 @default.
• W2900341805 creator A5016467945 @default.
• W2900341805 creator A5028743667 @default.
• W2900341805 creator A5033506735 @default.
• W2900341805 creator A5037999437 @default.
• W2900341805 creator A5046644939 @default.
• W2900341805 creator A5051340130 @default.
• W2900341805 creator A5051888634 @default.
• W2900341805 creator A5055817555 @default.
• W2900341805 creator A5073127696 @default.
• W2900341805 creator A5074920774 @default.
• W2900341805 creator A5081888684 @default.
• W2900341805 creator A5084056199 @default.
• W2900341805 creator A5085342849 @default.
• W2900341805 creator A5088720489 @default.
• W2900341805 creator A5090418139 @default.
• W2900341805 creator A5090605318 @default.
• W2900341805 date "2010-11-19" @default.
• W2900341805 modified "2023-10-18" @default.
• W2900341805 title "R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years." @default.
• W2900341805 doi "https://doi.org/10.1182/blood.v116.21.2805.2805" @default.
• W2900341805 hasPublicationYear "2010" @default.
• W2900341805 type Work @default.
• W2900341805 sameAs 2900341805 @default.
• W2900341805 citedByCount "2" @default.
• W2900341805 countsByYear W29003418052012 @default.
• W2900341805 crossrefType "journal-article" @default.
• W2900341805 hasAuthorship W2900341805A5004214099 @default.
• W2900341805 hasAuthorship W2900341805A5010189385 @default.
• W2900341805 hasAuthorship W2900341805A5016467945 @default.
• W2900341805 hasAuthorship W2900341805A5028743667 @default.
• W2900341805 hasAuthorship W2900341805A5033506735 @default.
• W2900341805 hasAuthorship W2900341805A5037999437 @default.
• W2900341805 hasAuthorship W2900341805A5046644939 @default.
• W2900341805 hasAuthorship W2900341805A5051340130 @default.
• W2900341805 hasAuthorship W2900341805A5051888634 @default.
• W2900341805 hasAuthorship W2900341805A5055817555 @default.
• W2900341805 hasAuthorship W2900341805A5073127696 @default.
• W2900341805 hasAuthorship W2900341805A5074920774 @default.
• W2900341805 hasAuthorship W2900341805A5081888684 @default.
• W2900341805 hasAuthorship W2900341805A5084056199 @default.
• W2900341805 hasAuthorship W2900341805A5085342849 @default.
• W2900341805 hasAuthorship W2900341805A5088720489 @default.
• W2900341805 hasAuthorship W2900341805A5090418139 @default.
• W2900341805 hasAuthorship W2900341805A5090605318 @default.
• W2900341805 hasConcept C126322002 @default.
• W2900341805 hasConcept C141071460 @default.
• W2900341805 hasConcept C2776694085 @default.
• W2900341805 hasConcept C2776907518 @default.
• W2900341805 hasConcept C2777058707 @default.
• W2900341805 hasConcept C2778336483 @default.
• W2900341805 hasConcept C2778476033 @default.
• W2900341805 hasConcept C2778559949 @default.
• W2900341805 hasConcept C2779338263 @default.
• W2900341805 hasConcept C2780653079 @default.
• W2900341805 hasConcept C2780790343 @default.
• W2900341805 hasConcept C2781413609 @default.
• W2900341805 hasConcept C71924100 @default.
• W2900341805 hasConcept C90924648 @default.
• W2900341805 hasConceptScore W2900341805C126322002 @default.
• W2900341805 hasConceptScore W2900341805C141071460 @default.
• W2900341805 hasConceptScore W2900341805C2776694085 @default.
• W2900341805 hasConceptScore W2900341805C2776907518 @default.
• W2900341805 hasConceptScore W2900341805C2777058707 @default.
• W2900341805 hasConceptScore W2900341805C2778336483 @default.
• W2900341805 hasConceptScore W2900341805C2778476033 @default.
• W2900341805 hasConceptScore W2900341805C2778559949 @default.
• W2900341805 hasConceptScore W2900341805C2779338263 @default.
• W2900341805 hasConceptScore W2900341805C2780653079 @default.
• W2900341805 hasConceptScore W2900341805C2780790343 @default.
• W2900341805 hasConceptScore W2900341805C2781413609 @default.
• W2900341805 hasConceptScore W2900341805C71924100 @default.
• W2900341805 hasConceptScore W2900341805C90924648 @default.
• W2900341805 hasLocation W29003418051 @default.
• W2900341805 hasOpenAccess W2900341805 @default.
• W2900341805 hasPrimaryLocation W29003418051 @default.
• W2900341805 hasRelatedWork W2243879287 @default.
• W2900341805 hasRelatedWork W2519601971 @default.
• W2900341805 hasRelatedWork W2546626751 @default.
• W2900341805 hasRelatedWork W2550234544 @default.
• W2900341805 hasRelatedWork W2574289250 @default.
• W2900341805 hasRelatedWork W2579244032 @default.
• W2900341805 hasRelatedWork W2584220752 @default.
• W2900341805 hasRelatedWork W2588140663 @default.
• W2900341805 hasRelatedWork W2591979964 @default.
• W2900341805 hasRelatedWork W2592055730 @default.
• W2900341805 hasRelatedWork W2730183342 @default.
• W2900341805 hasRelatedWork W2785371004 @default.
• W2900341805 hasRelatedWork W2968633560 @default.
• W2900341805 hasRelatedWork W2980014940 @default.
• W2900341805 hasRelatedWork W2986040534 @default.
• W2900341805 hasRelatedWork W2990683910 @default.
• W2900341805 hasRelatedWork W3028783617 @default.
• W2900341805 hasRelatedWork W3095146716 @default.
• W2900341805 hasRelatedWork W3159115531 @default.
• W2900341805 hasRelatedWork W3163797190 @default.
• W2900341805 isParatext "false" @default.

• next